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Abstract
Background: Expansion of polyglutamine-encoding CAG trinucleotide repeats has been identified
as the pathogenic mutation in nine different genes associated with neurodegenerative disorders.
The majority of individuals clinically diagnosed with spinocerebellar ataxia do not have mutations
within known disease genes, and it is likely that additional ataxias or Huntington disease-like
disorders will be found to be caused by this common mutational mechanism. We set out to
determine the length distributions of CAG-polyglutamine tracts for the entire human genome in a
set of healthy individuals in order to characterize the nature of polyglutamine repeat length
variation across the human genome, to establish the background against which pathogenic repeat
expansions can be detected, and to prioritize candidate genes for repeat expansion disorders.
Results: We found that repeats, including those in known disease genes, have unique distributions
of glutamine tract lengths, as measured by fragment analysis of PCR-amplified repeat regions. This
emphasizes the need to characterize each distribution and avoid making generalizations between
loci. The best predictors of known disease genes were occurrence of a long CAG-tract
uninterrupted by CAA codons in their reference genome sequence, and high glutamine tract length
variance in the normal population. We used these parameters to identify eight priority candidate
genes for polyglutamine expansion disorders. Twelve CAG-polyglutamine repeats were invariant
and these can likely be excluded as candidates. We outline some confusion in the literature about
this type of data, difficulties in comparing such data between publications, and its application to
studies of disease prevalence in different populations. Analysis of Gene Ontology-based functions
of CAG-polyglutamine-containing genes provided a visual framework for interpretation of these
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genes' functions. All nine known disease genes were involved in DNA-dependent regulation of
transcription or in neurogenesis, as were all of the well-characterized priority candidate genes.
Conclusion:  This publication makes freely available the normal distributions of CAG-
polyglutamine repeats in the human genome. Using these background distributions, against which
pathogenic expansions can be identified, we have begun screening for mutations in individuals
clinically diagnosed with novel forms of spinocerebellar ataxia or Huntington disease-like disorders
who do not have identified mutations within the known disease-associated genes.
Background
Nine different neurodegenerative disorders are known to
be caused by expansions of polyglutamine-encoding CAG
trinucleotide (CAGpolyQ) repeats in the following genes:
the HD gene in Huntington disease [1], ATN1 in denta-
torubral pallidoluysian atrophy or Haw River syndrome
[2,3],  AR  in spinal and bulbar muscular atrophy [4],
CACNA1A  in spinocerebellar ataxia SCA6 [5], TBP  in
SCA17 [6] and ATXN1, 2, 3, and 7 in SCA1 [7], SCA2 [8-
10], SCA3 (Machado-Joseph disease) [11], and SCA7 [12].
These disorders share similar clinical features which
include selective neuronal degradation associated with a
progressive neurological phenotype, but their respective
causative genes appear to have little functional or struc-
tural similarity, suggesting that functional genomics
approaches to identifying new gene-disease associations
will not be useful. The repeat expansion mechanism of
pathogenesis is a shared molecular feature, and this form
of mutation has only been exhaustively ruled out for a few
familial forms of SCA, and has not been examined at all
for the majority of patients who present with SCA or HD-
like disorders.
Despite recent advances in molecular diagnosis, the
majority of individuals clinically diagnosed with SCA do
not have identified mutations within the known disease-
associated genes [13]. There are 28 genetically distinct
SCAs identified by the Human Gene Nomenclature Com-
mittee (HGNC) [14], but only 13 causative genes are
known. Six genes cause SCA by CAGpolyQ expansions,
but the remaining 15 clinically-defined forms of SCA have
no known genetic mutation associated with them, and the
search for causative genes continues. It is likely that some
of these forms of SCA will be found to be caused by this
common mutational mechanism. Candidate genes for
SCA and HD-like disorders can be identified using a
whole-genome screening approach based on the compu-
tational identification of a common sequence we have
termed a Genomic Mutational Signature (GeMS). GeMS
are sequence patterns occurring in the normal genome
that, when mutated, cause disease – in this case CAG tri-
nucleotide repeats that encode an extended tract of
glutamine residues in the protein. A significant advantage
of this approach is that novel candidate disease genes are
identified and can then be screened for mutations in sin-
gle cases. This approach is not constrained by any require-
ment for additional family members, additional affected
patients, nor is a detailed family history required.
Partial lists of CAGpolyQ-containing genes identified
using classical [15-20] or computational methods [21-24]
have been published. Screening for CAG expansions in
one such gene list, in patients with hereditary ataxias, led
directly to the discovery of the causative gene for denta-
torubral pallidoluysian atrophy [2,16]. To date, there has
been no complete genome-wide analysis of the distribu-
tions of CAGpolyQ repeat lengths in a control population
in order to set the baseline from which to detect expan-
sions. Studies on a limited number of genes have revealed
that different genes have very different polyglutamine
tract (Q-tract) length distributions with some invariant
(CREBBP) [25] some bimodal (ATXN3) [26], some very
narrow (ATXN2) [26] and some broad distributions (AR,
ATN1, SMARCA2 and THAP11) [26-28].
The molecular nature of polyglutamine repeats
The amino acid glutamine (Q) is encoded by CAG and
CAA trinucleotides. Q-tracts in proteins are typically
encoded by mixtures of these two codons while expanded
Q-tracts in disease-causing genes are typically composed
of long uninterrupted repeats of the CAG trinucleotide
only. Long uninterrupted CAG repeats are known to be a
substrate for expansion mutation by a variety of mecha-
nisms. The underlying process is currently thought to
involve the generation of abnormal DNA structures
induced by factors such as replication slippage, DNA
repair and recombination, that can contribute to repeat
instability acting either separately or in combination [29-
32] and these mutations underlie pathogenic expansions
[33] and genetic anticipation [34,35]. Q-tracts encoded by
mixtures of CAG and CAA codons, however, are less prone
to suffer expansions [30,36,37]. The precise nucleotide
sequence of a repeat tract determines a particular allele's
susceptibility to large expansion mutations, while the
amino acid sequence – the Q-tract – in the context of the
whole protein determines the effect of a length change on
molecular and clinical phenotypes.BMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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Characteristics of known disease genes
One motivation for this research was to enable us to pri-
oritize candidate genes for polyglutamine expansion dis-
orders. Thus, we sought to identify hallmarks among the
known disease genes to which we could compare our data
on CAGpolyQ genes not yet associated with disease. Dis-
ease-causing CAGpolyQ-containing genes tend to be con-
sidered a homogeneous group in terms of their repeats,
with an often-cited pathogenic threshold of about 35
glutamines. In fact, a closer look at normal and patho-
genic characteristics of each reveals their unique qualities.
ATXN2 has a remarkably narrow distribution of Q-tract
lengths with very few alleles longer or shorter than the
modal length of 22Q [26,37]. In contrast, ATXN3 has a
broad bi- (or tri-) modal distribution of Q-tract lengths
[26]. Disease genes can also differ in the number of Q-res-
idues that separate the longest normal from the shortest
pathogenic allele. The longest normal ATN1  Q-tract is
36Q and the shortest disease allele has 48Q [26,38], while
a single residue separates normal (19Q) from pathogenic
(20Q) Q-tracts in CACNA1A [26,38]. Some disease genes
carry non-glutamine interruptions in their Q-tracts,
though their lengths are often reported as "repeat lengths"
as if they were pure Q-tracts. For example, normal ATXN1
has one to three CAT (coding for histidine, H) interrup-
tions near the middle of the Q-tract, but in SCA1 disease
alleles the repeat tracts are pure CAGpolyQ [39]. Clearly
one must be cautious in making assumptions about com-
mon features among polyglutamine expansion disease
genes when seeking to identify new disease-associated
genes.
At the sequence level, polyglutamine expansion disease
genes share several characteristics. They have long uninter-
rupted CAG tracts [29] and tend to have polymorphic Q-
tract lengths [26,36]. Analysis of both genomic DNA and
expressed sequence tags have shown that pure CAG-tract
length is correlated with Q-tract variance [36,40,41] and
interruptions provide stability to repeat tracts [36,37].
Finally, comparisons of orthologous human and rodent
genes show that the lengths of disease-associated Q-tracts
have a low level of conservation between species com-
pared with those that are not associated with disease
[29,42].
The products of the genes causing polyglutamine expan-
sion disorders do not all share a specific function, but the
phenotypic overlap of these disorders does suggest some
common functions in either their normal or mutated
states, or both. As early as 1989, researchers noted the
involvement of polyQ-containing genes in transcriptional
regulation [43]. This connection spans organisms from
yeast to humans [44-48] and known disease-causing
genes like HD, TBP and ATXN7 are directly involved in
transcription and transcriptional regulation [49-55].
ATXN1 and ATXN2 are thought to be involved in RNA
metabolism [56,57] while CACNA1A is the only ion chan-
nel gene known to cause a polyglutamine expansion dis-
order [5]. The normal function of a gene product and the
role of the Q-tract in that protein determine the distribu-
tion of repeat lengths in the normal population and the
threshold for pathogenic expansion for each gene. There-
fore, the functions of CAGpolyQ-containing genes must
be assessed in conjunction with the normal levels of
repeat polymorphism in order to prioritize candidate
genes for polyglutamine expansion disorders.
Summary
Using the human genome reference sequence [58,59] and
Ensembl annotated genes [60] we performed a genome-
wide computational identification of all candidate genes
containing a specific GeMS sequence, CAGpolyQ repeats.
We used fragment analysis to assess the CAG-tract lengths
of these candidate genes in a large control population. We
also applied two methods of analyzing the potential func-
tions of these genes based on the Gene Ontology (GO)
system of functional classification [61] in order to identify
and visualize the network of functional relationships
among the CAGpolyQ-containing genes in the human
genome. Using related approaches, Lavoie and colleagues
identified polyalanine-containing genes in the human
genome and assessed their normal levels of polymor-
phism [62]. Functional analysis revealed that the majority
of polyalanine-containing genes have roles in transcrip-
tional regulation [62].
In characterizing the Q-tract length distributions for 64
CAGpolyQ tracts in 62 genes in the human genome, we
find that each Q-tract has a unique distribution of Q-tract
lengths. The best predictors of known disease genes were
occurrence of a long uninterrupted CAG-tract in their ref-
erence genome sequence and high Q-tract length variance
in the normal population. Therefore, we used these
parameters to identify eight priority candidate genes for
polyglutamine expansion disorders. The majority of CAG-
polyQ-containing genes are involved in transcriptional
regulation and neurogenesis. We provide a visual frame-
work for interpretation of new information on CAGpolyQ
gene functions and their biomolecular interactions.
Results
Identification of CAGpolyQ-containing Genes
CAGpolyQ repeats were identified on the basis of having
tandemly repeated CAG trinucleotides in the sequence
within the boundaries of a known gene that had five or
more tandem glutamine residues in its peptide sequence
(see Methods for detailed description of approach and
data sources). Build 33 of the human genome sequence
[58] contained 436 CAG trinucleotide repeats in total.
Sixty-six of these CAG repeats lay in glutamine-codingBMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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sequences in genes including all nine genes in which
mutation by expansion of their CAGpolyQ repeat tract is
known to cause a neurodegenerative disorder (Table 1).
Distributions of Q-tract Lengths
Using PCR amplification and ABI fragment analysis we
established the range of CAGpolyQ tract lengths for 64
targets (in 62 genes) in a set of healthy individuals of
mixed ethnic background (Table 1, Additional file 1). We
screened at least 130 normal alleles for each target (mean
162), including X-linked genes, giving us 99% confidence
that 95% of the whole population lie between the mini-
mum and maximum values in our sample (95% toler-
ance; see Methods), with the exception of four targets for
which we screened slightly fewer alleles due to technical
limitations:  ATXN2  and  CACNA1A  (94% tolerance),
FOXP2 and RUNX2 (93% tolerance). Table 1 summarizes
data for 66 CAGpolyQ repeat targets in 64 genes.
Known disease genes have long uninterrupted CAG-tracts and high 
Q-tract length variances
We sought in our data some hallmark of the nine known
disease genes that would allow us to prioritize candidates
among the 54 genes not yet associated with CAGpolyQ
expansion disorders. Sorting CAGpolyQ repeats by
increasing Q-tract length variance (Table 1) clustered dis-
ease genes in the top one third of 64 targets. Known dis-
ease gene Q-tract length variances ranged from 0.79
(ATXN2) to 29.2 (ATXN3). The highest Q-tract length var-
iances of all targets were observed in four known disease
genes: ATXN3, ATN1, AR and HD. The least polymorphic
disease target, ATXN2, is distinguished from other disease
genes by its previously documented tight distribution of
Q-tract lengths [26].
Q-tracts are made up of lengths of CAG codons that can
be pure or interspersed with one or more CAA codons.
Length polymorphism tends to occur within CAG-tracts.
Sorting CAGpolyQ repeats by the length of their longest
uninterrupted CAG-tract in the reference genome clus-
tered disease genes in the top half of 64 targets. This was
increased to the top one third if ATXN3 was excluded due
to its reference genome sequence reflecting the low mode
of a bimodal distribution of repeat tract lengths (see graph
in Additional file 2). Disease gene CAG-tract lengths
ranged from 10 (ATXN7) to 22 (AR) and the longest unin-
terrupted CAG-tracts of all targets occurred in four disease
genes: AR (22 CAG), HD (19 CAG), TBP (19 CAG) and
ATN1 (15 CAG).
The length of the longest uninterrupted CAG-tract in the
reference genome for each target (e.g. CAG13CAA1CAG9
has CAG-tract length of 13; see Table 1) was positively cor-
related with its level of polymorphism (correlation = 0.62,
ATXN3  excluded; Figure 1). Given this association
between long CAG-tracts and high Q-tract length vari-
ance, we divided all targets in two groups at the median
CAG length of eight and tested the null hypothesis that
variances were equal in the two groups. Q-tract length var-
iances were indeed higher with longer CAG-tracts (p =
0.002, 1-tailed heteroscedastic t-test).
Mean or maximum Q-tract length failed to yield any sig-
nificant clustering of disease genes, and mean Q-tract
length was only very weakly correlated with Q-tract length
variance (correlation = 0.12). Underlying this relationship
is the fairly weak correlation of uninterrupted CAG-tract
length with mean Q-tract length (0.31, ATXN3 excluded).
Mixtures of CAG and CAA codons making up the Q-tract
account for this. One telling example is FOXP2 which had
the longest mean and maximum Q-tract lengths but rela-
tively little variance in Q-tract length. In fact, FOXP2 had
the second-shortest uninterrupted CAG-tract of all 66 tar-
gets. Based on our analysis, this low level of polymor-
phism is predicted by the short pure CAG repeat length.
Sorting targets according to other parameters also failed to
yield any significant clustering of disease genes. These
included sorting by the proportion of alleles with Q-tract
lengths longer than mean + 1 SD, and by repeat purity,
which was a combined measure of both the length of the
longest uninterrupted CAG-tract and the total Q-tract
length.
Priority candidates for polyglutamine expansion disorders
A plot of CAG length versus Q-tract length variance for
each target allowed us to identify eight genes as priority
candidates for polyglutamine expansion disorders (Figure
1). We selected genes that had uninterrupted CAG-tracts
equal to or longer than 10 CAG (the shortest uninter-
rupted CAG-tract in a known disease gene, ATXN7) and
had Q-tract length variance equal to or higher than 0.79
(the lowest Q-tract variance in a known disease gene,
ATXN2). All eight priority candidates: C14orf4, KCNN3,
KIAA2018,  MEF2A,  NCOR2,  RAI1,  SMARCA2, and
THAP11 are expressed in normal brain [63-66]. This list is
not meant to be exhaustive, but rather a list of the top
eight genes prioritized according to two hallmarks of
known disease genes.
Twelve invariant CAGpolyQ repeats have short CAG-tracts
In this set of 64 CAGpolyQ repeats, having at least four
tandem CAG codons coding for five tandem glutamine
residues, mean Q-tract length ranged from five to 39.8
(Table 1). Twelve repeats in eleven genes, including CREB-
binding protein (CREBBP) for example, had no changes
in Q-tract length in as many as 212 alleles tested. An addi-
tional six repeats were essentially invariant with only one
out of as many as 184 alleles differing in length by one Q-
residue (Table 1). The twelve invariant repeats had unin-BMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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Table 1: Q-tract length variation in genes containing polyglutamine-encoding CAG-type trinucleotide repeats, sorted by Q-tract
Chromosome
Band
Gene Namea Repeat Sequence from Reference 
Genome (sense strand)b
Expected 
Q-tract 
Length from 
Reference 
Genomec
Nd Observed
Q-tract
Length
Min-Max
Q-tract
Mean
Q-tract
Variance
17p13.2 MINK1* G4N1G5 Q4LQ5 (SwP) 162 5 – 5 5.0 0
9q34.11 CIZ1 G6 Q6 154 6 – 6 6.0 0
7q36.2 PAXIP1L* G7 Q7 168 7 – 7 7.0 0
11q24.3 PRDM10 G8 Q8 172 8 – 8 8.0 0
4q31.1 MAML3a* G9 Q9 156 8 – 8 8.0 0
6p21.1 TFEB G6A1G3 Q10 162 10 – 10 10.0 0
19p13.11 CHERP G6A1G5 Q12 192 12 – 12 12.0 0
12q21.2 PHLDA1 G5A1G6A2G1 Q15 212 14 – 14 14.0 0
16p13.3 CREBBP G4A1G3A2G2A1G4A1 Q18 158 18 – 18 18.0 0
4q31.1 MAML3b* G3A1G3A1G1A1G8 Q18 166 18 – 18 18.0 0
20q11.22 NCOA6* G4A4G8A2G1A1G2A2G1 Q25 166 25 – 25 25.0 0
Xq13.1 MED12* G5A1G2A1G1A1G5A1G1A1G7N4G6 Q26X4Q6 205 26 – 27 26.0 0
20q13.12 PRKCBP1 G7A1 Q8 152 8 – 9 8.0 0.01
15q24.1 ARID3B G8A2G1 Q11 212 11 – 12 11.0 0.01
22q11.21 PCQAPa G4A1G3N1G5N3G7A1G3N8G3N5G5N1G8 Q8FQ5X3Q11
X16Q5LQ8
152 11 – 12 11.0 0.01
3p24.3 SATB1 G1A1G3A1G1A1G7 Q15 174 15 – 16 15.0 0.01
6q16.2 POU3F2 G3A1G1A1G3A1G2A1G6A1G1 Q21 148 21 – 22 21.0 0.01
Xq22.3 FRMPD3 G4A3G4A3G3A3G7 Q27 (SwP) 184 26 – 27 27.0 0.01
2q35 TNS G9 Q9 178 9 – 11 9.0 0.02
19p13.12 BRD4 G5N1G1N1A1G4A1G1A1 Q5RQEQ8 140 8 – 9 8.0 0.03
12p13.31 PHC1 G5A2G1A1G2A1G3 Q15 170 13 – 15 15.0 0.05
9q32 C9orf43 G6A1G1 Q8 168 8 – 9 8.1 0.07
1q21.3 TNRC4 A1G8A1G4A1 Q15 150 15 – 18 15.0 0.08
17q12 SOCS7 G7A1 Q8 (SwP) 134 8 – 9 8.1 0.12
1p31.1 ST6GALNAC5 G7A1G4 Q12 150 12 – 14 12.1 0.13
15q26.1 POLG G10A1G2 Q13 164 13 – 15 13.1 0.16
22q13.1 TNRC6B G8 Q8 166 7 – 8 7.8 0.17
12q13.12 MLL2* G5N1A1G1A1G1A1N1G7N1A1G1A1G1A1N1 
G2A1G1N1A1G2A1G4N1A2G3A1G1N1A1G2 
A1G2N1A1G1A1G1A3G3N1A1G3A1G3
Q5LQ5LQ7LQ
5LQ4LQ8LQ7 
LQ6LQ10FQ8
184 8 – 11 10.2 0.21
7p14.1 POU6F2 G10 Q10 168 6 – 11 10.0 0.22
Xq28 CXorf6 G1A1G8A1N92G5A1G4 Q11X92Q10 168 11 – 12 11.6 0.25
12p13.33 DCP1B G9A1 Q10 136 10 – 12 10.5 0.26
17q23.2 VEZF1 G12A6 Q13 (through 
intron)
176 8 – 15 13.1 0.29
22q11.21 PCQAPb G3A1G2N9A2G1A1G12 Q6X9Q16 152 12 – 18 16.1 0.34
3p14.1 MAGI1 G5A1G3A1G10 Q20 168 16 – 21 20.3 0.36
4q21.21 BMP2K G8A1G1A1G4A1G1A1G9 Q27 148 23 – 28 26.9 0.36
16q22.1 NFAT5* G5A1G3A1G3A3G1 Q17 168 11 – 19 17.0 0.37
12p13.31 ZNF384 G14A1G1 Q16 214 11 – 20 15.2 0.47
22q12.1 MN1* A1G9A1G6A1G1A1G1A1G6 Q28 180 26 – 30 28.7 0.53
12q24.33 EP400 G6A2G14A1G4A1G1 Q29 158 28 – 31 28.8 0.53
12q23.2 ASCL1 G12 Q12 148 9 – 15 12.3 0.65
6q25.3 ARID1B G7A1G7A1G1A1 Q18 152 16 – 23 17.7 0.69
11q21 MAML2 G1A1G2A1G13A1G5A1G1A1G1A1G1A1G2N 
5A2G1A1G3N5A1G5A2G5A3G1A2G6A2
Q31X5Q7X5Q
27 (through 
intron)
168 27 – 31 28.3 0.75
12q24.12 ATXN2 G13A1G9 Q23 124 17 – 27 22.2 0.79
9p24.3 SMARCA2 G1A2G3A1G13A1G2 Q23 130 18 – 24 22.7 0.79
20q13.12 NCOA3 G6A1G9A1G1A1G1A1G1A1G2A1G2A1 Q29 150 26 – 31 28.4 0.80
17p11.2 RAI1 G13A1 Q14 184 11 – 17 14.6 0.84
7q31.1 FOXP2* G4A1G4A2G2A2G3A5G2A2G5A1G5A1G1 Q40 100 34 – 40 39.8 0.85
3p14.1 ATXN7 G10 Q10 184 7 – 14 10.4 0.89
19q13.2 NUMBL G6A1G1A1G7A1G2A1 Q20 156 18 – 20 18.7 0.93BMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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12q24.31 NCOR2 G3A2G12 Q16 (through 
intron)
172 13 – 20 16.9 0.95
15q26.3 MEF2A G11 Q11 174 8 – 16 10.2 1.13
14q24.3 C14orf4 A1G1A1G1A1G6A1G10A2G1 Q25 (through 
intron)
150 20 – 31 23.4 1.17
3q13.2 KIAA2018 G11A1G1A4 Q14 (through 
intron)
150 11 – 16 12.6 1.44
1q21.3 DENND4B A1G5A1G9 Q16 156 13 – 17 15.2 2.04
6p22.3 ATXN1 G12T1G1T1G14 Q12HQHQ14 130 11 – 21 14.6 2.23
6q27 TBP G3A3G8A1G1A1G19A1G1 Q38 158 30 – 41 36.9 2.26
19p13.3 CACNA1A G13 Q13 112 7 – 16 12.1 2.42
16p12.1 TNRC6A G4A1G3 Q8 166 4 – 8 7.2 2.50
6p21.1 RUNX2 A1G3A1G4A1G6A1G6 Q23 100 18 – 30 22.5 3.04
16q22.1 THAP11 G3A1G5A1G2A1G5A1G10 Q29 170 18 – 30 28.5 3.12
1q22 KCNN3 G7A1G4N25G14 Q12X25Q14 170 15 – 25 20.3 3.98
4p16.3 HDe G19A1G1 Q21 252 9 – 33 17.2 7.18
Xq12 AR G22A1N5G6 Q23X5Q6 180 14 – 33 23.7 9.34
12p13.31 ATN1 G1A1G1A1G15 Q19 168 11 – 27 17.6 11.6
14q32.12 ATXN3 G2A1N1G1A1G8 Q3KQ10 168 10 – 27 17.8 29.2
2q37.1 TNRC15 G6 Q6 n.d. n.d. n.d. n.d.
aBoldface   text marks a gene known to cause disease by expansion of a   polyglutamine-encoding CAG trinucleotide repeat. 'a' and 'b' after MAML3   
and PCQAP denote two targets within these genes. Genes marked with an   asterisk (*) contain an additional repeat target that was not screened   
in this study.
bG denotes   "CAG", A denotes "CAA" and N denotes a non-glutamine codon, each   followed by the number of tandem repeats of that codon. 
Boldface text   marks the longest uninterrupted CAG-tract.
cX indicates a non-glutamine amino acid; SwP indicates peptide sequence obtained from SwissProt record
dN denotes number of alleles screened
eData for N, Observed Q-tract Length Min-Max, Q-tract Mean, Q-tract Variance, taken from Andres et al. (26)
Table 1: Q-tract length variation in genes containing polyglutamine-encoding CAG-type trinucleotide repeats, sorted by Q-tract 
terrupted CAG-tracts from four to nine repeat units long
but had mean Q-tract lengths evenly distributed from five
to 26 residues (Table 1). Thus, a lack of polymorphism
was restricted to relatively short pure CAG-tracts but their
Q-tract lengths varied widely. This again emphasizes the
utility of using pure CAG-tract length rather than Q-tract
length in assessments of length polymorphism.
Each CAGpolyQ repeat has a unique distribution of Q-tract lengths
The two allele frequency distributions of Q-tract lengths
in Figure 2 provide examples of the 64 CAGpolyQ repeats
we analyzed. ATXN3 had a unique bi- or tri-modal distri-
bution that is virtually identical to published data [26].
RAI1, a priority candidate disease gene with a long CAG-
tract and relatively high Q-tract variance, had a simpler
distribution that is consistent with the published Q-tract
length range [62]. The 64 plots of allele frequency distri-
butions of Q-tract lengths for each CAGpolyQ repeat illus-
trate clearly that there is no single pattern that is typical of
Q-tract length distributions across the human genome
(Additional file 2).
Functional classification of CAGpolyQ-containing genes
Browsing descriptions associated with the 64 CAGpolyQ
genes suggested an over-representation of genes involved
in transcriptional processes and genes involved in chro-
matin architecture, and thyroid hormone receptor bind-
ing. We assessed these and other observations using GO-
based classification of these genes to determine whether
specific functional categories are statistically overrepre-
sented, to visualize the network of functional relation-
ships among CAGpolyQ-containing genes, and to
determine whether priority candidates for polyglutamine
expansion are associated with one or more specific GO
terms.
GO over-representation analysis
We used GoMiner [67] to look for statistical over-repre-
sentation of CAGpolyQ genes in GO terms in the top four
levels of the three GO categories: biological process,
molecular function, and cellular component. GO term
descriptions can be viewed at the Gene Ontology website
[68]. GoMiner contained gene name-GO term annota-
tions for 56 of our 64 genes against a background of
13,598 HGNC genes. Genes without GO term assign-
ments at the time of this analysis were: C14orf4, C9orf43,
CXorf6,  DENND4B,  FRMPD3,  KIAA2018,  TNRC15  and
TNS. Our null hypothesis was that the genes of interest
would be distributed among the chosen GO terms in the
same proportions as the background set. GO terms with
p-values below the significance threshold (p = 0.05) were
considered to be over-represented among CAGpolyQ
genes. In negative control experiments (see Methods) we
found no over-representation in GO terms under molecu-
lar function in 100 replicates. Under biological process,
three out of 100 replicates each had one over-representedBMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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GO term. Under cellular component, one out of 100 rep-
licates had one over-represented GO term and one out of
100 replicates had two over-represented GO terms.
Over-representation analysis confirmed these 56 CAG-
polyQ genes' functional association with transcription
and revealed some specific details. There were six signifi-
cant GO terms under molecular function (Table 2). These
included 13.4-fold over-representation of transcription
coactivator activity, which is a child term of the 8.8-fold
over-represented transcription cofactor activity. CAG-
polyQ transcriptional coactivators on our gene list
include:  ARID1B,  CREBBP,  MAML2,  MAML3,  MED12,
MEF2A, NCOA3, NCOA6, and SMARCA2. Transcription
factor binding was 8.3-fold over-represented, including
the transcription coactivator genes above, as well as HD,
NCOR2 and TBP. Half of the 56 genes bind DNA. There
were five significant GO terms under biological process
(Table 2), with the most specific, positive regulation of
metabolism, 6.5-fold over-represented (MAML2,
CREBBP,  RUNX2,  ARID1B,  NCOA6,  NFAT5, and
MAML3). There were seven significant GO terms under
cellular component (Table 2), with nucleoplasm 4.1-fold
over-represented. Genes in over-represented GO catego-
ries are listed in Additional file 3 (Biological Process),
Additional file 4 (Molecular Function) and Additional file
5 (Cellular Component).
Shared GO-term analysis
To delve deeper into the possible functional relationships
among genes containing CAGpolyQ repeats, we devel-
oped a method for quantitative comparison of GO terms
annotated to each gene product, based on the structure of
the GO graph (AMM, SLB, BFFO, manuscript in prepara-
tion). Briefly, given a pair of genes, their GO term annota-
tions, and a comparison scoring function for GO terms,
we calculated similarity scores for every pair of GO terms
for that pair of genes. GO term pairs scoring above a
threshold were used to construct a graph where each node
represents a gene and weighted edges between nodes rep-
resent pairs of GO term annotations and their scores.
Genes were grouped by a simple visual clustering algo-
rithm that assigns shorter lengths to edges with higher
weights (i.e. more similar shared GO terms). Because a
gene may have multiple shared GO terms with other
genes, this method allowed us to cluster the functions of
genes that share terms on different branches and at differ-
Example distributions of normal Q-tract lengths Figure 2
Example distributions of normal Q-tract lengths. (A) 
ATXN3, ataxin 3 (B) RAI1, retinoic acid receptor 1.
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Relationship between length of longest uninterrupted CAG- tract and Q-tract length variance Figure 1
Relationship between length of longest uninter-
rupted CAG-tract and Q-tract length variance. (A) All 
targets. HD Q-tract length variance from Andres et al. [26]. 
Correlation = 0.62, not including ATXN3. (B) Higher resolu-
tion view of targets with Q-tract length variance < 4.0. 
Dashed lines at 10 CAG and 0.79 variance represent the cut-
off for identifying candidate genes for polyglutamine expan-
sion disorders. See text for list of genes falling in this area.
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ent levels of the gene ontology. Related functions go
unnoticed without this clustering.
Only seven gene pairs scored above the cutoff (estimated
99th percentile; described in Methods) for the cellular
component category (Additional file 6) so we did not con-
sider this category further. There were 544 gene pairs with
scores above the cutoff in the biological process category,
representing 45 genes. There were 503 pairs among 42
genes in the molecular function category. The functional
relationships among these CAGpolyQ genes are illus-
trated in Figure 3. GO terms and the genes that share them
are listed in Additional file 7 (Biological Process), Addi-
tional file 8 (Molecular Function) and Additional file 6
(Cellular Component).
Based on our analysis of relationships among GO terms
shared by two or more genes, CAGpolyQ genes in the
human genome clustered primarily under two major bio-
logical processes: DNA dependent regulation of transcrip-
tion, and neurogenesis (Figure 3A). Other processes
included establishment and/or maintenance of chroma-
tin architecture and post-translational modifications.
Since there were few functional clusters, it was not surpris-
ing that all but one known disease gene and most priority
candidate genes were involved in DNA dependent regula-
tion of transcription and in neurogenesis (Figure 3A).
ATXN7, the one disease gene excluded from the cluster
involved in DNA dependent regulation of transcription,
was recently shown to be an integral component of the
TFTC (TATA-binding protein-free TAF-containing) com-
plex and the STAGA (SPT3/TAF9/GCN5 acetyltransferase)
complex involved in transcriptional regulation [52-54].
Consistent with their predominant classification in DNA
dependent regulation of transcription, DNA binding was
the primary shared molecular function among these 64
genes (Figure 3B). Known disease genes were involved in
DNA, calcium and zinc binding and HD was classified as
having transcription corepressor activity (Figure 3B). All
but one priority candidate gene had DNA binding activity
according to current GO annotations. CAGpolyQ genes
with invariant Q-tract lengths were not limited to any one
biological process or molecular function.
Discussion
Our findings build on previous work indicating that unin-
terrupted CAG-tract length, not the Q-tract length
encoded by CAG plus CAA codons, influences the degree
of polymorphism of a Q-tract. Uninterrupted CAG-tract
length and Q-tract length variance are the most useful
parameters in characterizing known disease genes and
identifying candidate genes for expansion disorders. At
one extreme, zero variance CAGpolyQ repeats – those that
do not tolerate changes in Q-tract length – can likely be
excluded as candidates for polyglutamine expansion dis-
orders. The shapes of Q-tract length distributions differed
widely between various loci across the genome. Thus, the
data presented here for allele length distributions for 64
Table 2: Functional classification of CAGpolyQ genes: Gene Ontology over-representation analysis.
Gene Ontology term (levels) GO ID Candidate genes in GO term Fold* Enrichment
Biological Process
regulation of biological process (1) GO:0050789 37 2.3
regulation of physiological process (2) GO:0050791 36 2.5
regulation of metabolism (3) GO:0019222 29 3.0
positive regulation of metabolism (4) GO:0009893 7 6.5
nucleobase, nucleoside, nucleotide and nucleic acid
metabolism (4) GO:0006139 34 2.5
Molecular Function
transcription regulator activity (1) GO:0030528 24 4.0
transcription cofactor activity (2,4) GO:0003712 11 8.8
transcription coactivator activity (3,5) GO:0003713 9 13.4
nucleic acid binding (2) GO:0003676 35 2.8
DNA binding (3) GO:0003677 28 3.1
transcription factor binding (3) GO:0008134 12 8.3
Cellular Component
organelle (1) GO:0043226 43 1.7
membrane-bound organelle (2) GO:0043227 43 1.9
intracellular (2) GO:0005622 47 1.5
intracellular organelle (2,3) GO:0043229 43 1.7
intracellular membrane-bound organelle (3,4) GO:0043231 43 1.9
nucleus (3,4,5) GO:0005634 41 2.7
nucleoplasm (4,5,6) GO:0005654 11 4.1
All levels for each GO term are indicated, with boldface indicating one path through the GO
*p < 0.00004 for all GO terms listed except nucleoplasm, p = 0.0001.BMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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Functional classification of CAGpolyQ genes: shared Gene Ontology term analysis Figure 3
Functional classification of CAGpolyQ genes: shared Gene Ontology term analysis. Known disease genes are marked with a 
'D', candidate disease genes are marked with a 'C' and genes with invariant Q-tracts (Table 1) are marked with an 'I'. Clusters 
of genes are labeled with the GO terms that best described each cluster. GO terms shared by gene pairs are listed in Addi-
tional file 7 and Additional file 8. Genes not represented in a graph either had no annotation under that GO namespace or did 
not share a GO term with a score above the 99th percentile. (A) Biological process. Genes not represented: ARID1B, ATXN1, 
ATXN2, BRD4, C9ORF43, DCP1B, HD, DENND4B, FRMPD3, MAML2, PAXIP1L, PHC1, PHLDA1, SOCS7, THAP11, TNRC15, 
TNRC6A, TNRC6B and TNS. (B) Molecular function. Genes not represented: ATN1, ATXN1, ATXN3, BRD4, C14ORF4, C9ORF43, 
CHERP, DCP1B, KCNN3, DENND4B, FRMPD3, MAML2, NUMBL, PAXIP1L, PCQAP, PHLDA1, SOCS7, ST6GALNAC5, TNRC15, 
TNRC6A, TNRC6B and TNS.
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Q-tracts in 62 genes with detailed conditions for their
screening, will be invaluable for identifying putative
expansion mutations in candidate genes not yet associ-
ated with CAGpolyQ-type neurodegenerative disorders.
All nine known polyglutamine expansion disorder genes
are involved in DNA-dependent regulation of transcrip-
tion or in neurogenesis, as are all of the well-characterized
priority candidate genes identified in this study.
Many groups have published lists of CAGpolyQ-contain-
ing genes identified using classical [15,17-20] or compu-
tational methods [21-24]. The content of each
computationally-derived list differs slightly depending on
the repeat detection algorithms and gene data sets used
but they are largely the same. Tandem Repeat Finder, used
in this study under default parameters, is not guaranteed
to find all CAGpolyQ repeats, but it is likely that the vast
majority of long repeats were found. Our approach is val-
idated by its detection of all nine genes known to cause
diseases by expansion of CAGpolyQ repeats. This study of
the normal levels of polymorphism of human CAGpolyQ
repeats is the most exhaustive conducted to date.
Our allele frequency distributions match those published
for known disease genes AR  [69],  ATN1  [2,3,26,70],
ATXN1  [26],  ATXN2  [26],  ATXN3  [26,70],  ATXN7
[70,71], CACNA1A [26,70], and TBP [70,72]. The same is
true for CAGpolyQ repeats in other genes whose Q-tract
lengths have been found to be invariant like CREBBP [25]
and MED12 [19], moderately polymorphic FOXP2 [73],
NCOA3 [25,26,74], POLG [75], RAI1 [76], SMARCA2 [28]
or highly polymorphic THAP11 [28] and KCNN3 [26,77].
Differences in apparent repeat lengths between this study
and published data for ATXN1  [26,70] and ATXN3
[26,70] exist because we report repeat lengths based on
the longest pure Q-tract while Andres et al. [26] and Juvo-
nen et al. [70] report "repeat lengths" that contain non-
glutamine amino acids. For ATN1, the shape of our distri-
bution matches published data but our distribution is
increased by two to four glutamine residues.
Among our eight priority candidate genes some features
are already known. CAG length variation in RAI1  is
responsible for 4.1% of age of onset variability in SCA2
[76]. Huang et al. [42] identified RAI1 (called RAI2 in that
paper) and NCOA3 as candidate disease genes by virtue of
their long CAG tracts and the fact that their mouse and rat
orthologues had Q-tracts less than half the size of the
human repeats. In our study, NCOA3 lay just below the
threshold for priority candidate disease genes, with nine
CAG while priority candidates had ten CAG. KCNN3
CAG-tract length differences have been associated with
anorexia [78] and with schizophrenia and bipolar disor-
der but these associations are controversial [79].
SMARCA2 and THAP11 were previously identified as can-
didates by Pandey [28] based on their relatively long
uninterrupted CAG-tracts. Four genes identified by Huang
et al. [42] as candidate genes of interest fell far below our
threshold of Q-tract variance so we do not consider them
to be priority expansion disease candidates. These were
DCP1B, MAML3 (called TNRC3 in Huang et al.), POLG
(called NFYC in Huang et al.) and POU6F2 (called RPF-1
in Huang et al.).
Q-tract lengths for many genes do not have a normal dis-
tribution and differ widely between loci, as previously
observed [27,36]. Even different disease genes have very
different Q-tract length distribution shapes with different
minima and maxima in normal populations and different
minimum disease allele lengths so it is critical to charac-
terize each distribution without making generalizations
between loci. A gene containing more than one CAG-
polyQ repeat can have two invariant repeats (MAML3) or
a combination of invariant and variant repeats (PCQAP).
Orthologous repeats in human and mouse genomes can
have very different levels of polymorphism: human
VEZF1 has a polymorphic Q-tract (this study) while the
corresponding Q-tract in its mouse orthologue is invari-
ant [80].
Long pure repeats expand
Alba and colleagues [29,30,81] have clearly shown that,
with respect to evolutionary processes, there are two
classes of Q-tracts in human proteins: those whose lengths
are conserved between human and mouse orthologues,
and those whose lengths differ. Length-conserved polyQ
repeats tend to be encoded by mixtures of CAG and CAA
codons and are likely to be restricted in length by purify-
ing selection. PolyQ repeats whose lengths vary between
human and mouse tend to be encoded by longer pure
CAG-tracts that evolve nearly neutrally [29,30,81]. Our
data on Q-tract polymorphism within a normal human
population corroborates their between species data and
builds on previous work, with longer pure CAG-tracts
having higher Q-tract length variance and invariant CAG-
polyQ repeats having relatively short pure CAG-tracts
[40,41]. Again, the extremes reinforce the rules; FOXP2
with a short 5-CAG repeat has the longest mean Q-tract
length of all candidate genes but a low level of polymor-
phism.
Correlation of uninterrupted CAG length with Q-tract
length variance is consistent with work on dinucleotide
repeats [82] and on tetra- and penta-nucleotide repeats
[83]. For all of these, the level of polymorphism increases
with the number of pure repeats, and non-polymorphic
repeats have the shortest pure repeat tracts. Similarly, in
the HD gene, as CAG repeat number increases, there is a
significant increase in the frequency of expansion muta-BMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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tions and the mean number of repeats added per expan-
sion [34].
Pure CAG length is not the only factor determining repeat
instability. An in-frame interruption in a CAG-tract has a
stabilizing influence over and above that of reducing the
pure CAG-tract length. In yeast, dinucleotide repeats with
a single dinucleotide interruption in the middle of the
tract are five times more stable than a pure repeat of the
same length [84]. SCA1 disease alleles of the ATXN1 gene
all contain uninterrupted tracts of CAG repeats while vir-
tually all normal alleles have one to three CAT (coding for
histidine) interruptions in the middle of the Q-tract [39].
Other factors underlying repeat instability include differ-
ent repair mechanisms [32], flanking sequence elements
[85,86], CpG methylation, and nucleosome and replica-
tion origin positioning [86-88].
Rozanska et al. [89] recently published a large study that
complements our results, analyzing repeat lengths and
interruption patterns in a normal Polish population. They
determined that the length of uninterrupted repeat tract in
the most frequent allele for a locus is correlated with the
degree of length polymorphism for that tract, and provide
further evidence for a stabilizing effect of repeat interrup-
tions. Trinucleotide repeat expansion disease genes were
found to have a higher proportion of long repeat alleles
than those not associated with disease [89].
Inferences about repeat lengths and disease prevalence
Lack of detailed reporting of repeat sequence lengths in
disease genes, such as Q-tract lengths in ATXN1  and
ATXN3 are a potential source of confusion in the literature
and highlight the difficulties in comparing Q-tract length
distributions for the same genes from different publica-
tions. The amino acid sequence of the most common nor-
mal ATXN1 repeat tract is Q12H1Q1H1Q14 [37] but it is
frequently reported as 29 "repeats" and the ATXN3 repeat
tract, Q3K1Q10, is reported as 14 "repeats" [26]. Non-
glutamine interruptions in a Q-tract are critical to pheno-
type, so it is misleading to report these as "Q repeats" or
"CAG repeats". For this reason, we reported all target Q-
tract lengths based on the longest uninterrupted Q-tract
(encoded by CAG/CAA) in the reference genome (Table 1,
Additional file 2).
Measuring Q-tract lengths in affected individuals enables
identification of putative repeat expansions outside the
normal range, but more in depth characterization requires
precise determination of the underlying amino acid and
nucleotide sequences of individual alleles. Characteriza-
tion of each allele at the nucleotide sequence level in addi-
tion to the normal (wild-type) Q-tract length distribution
will be critical in better identifying candidate CAGpolyQ
genes not yet associated with disease, determining which
alleles at a given locus are prone to expansion, and for dis-
ease genes, characterizing allele repeat sequences with
respect to disease prevalence in a given population [33].
As has been expertly laid out by Sobczak and Krzyzosiak
[37] repeat interruption patterns in a given target can dif-
fer between populations, even when Q-tract length distri-
butions are similar. Repeat interruption characteristics are
not commonly studied, but reporting overall repeat
lengths in the absence of repeat interruption patterns may
be quite misleading in studies of allele lengths as they
relate to disease prevalence in a given population
[37,70,90]. Juvonen and colleagues [70] recently reported
that the frequencies of large normal alleles at SCA loci
were poor predictors of the prevalence of the respective
diseases in Finland but Q-tract lengths were assayed with-
out reporting CAG-tract interruption patterns in different
alleles. A different picture might be revealed by character-
ization of repeat interruption patterns at each SCA locus
in that population.
The genotype-phenotype connection
Q-tract length variance is influenced both by specific
sequence characteristics and by the specific role of the Q-
tract within a protein's structure and function. AR pro-
vides an excellent example of this balance. The AR Q-tract
in the reference genome has a very long pure CAG-tract of
22 CAGs, consistent with its high length variance. The
CAGpolyQ tract in the AR protein lies in its N-terminal
transactivation domain which interacts with the C-termi-
nal ligand binding domain (the N/C interaction). Bucha-
nan et al. [69] found no changes in in vitro N/C interaction
for Q-tract lengths of 16 to 29 but shorter or longer tracts
resulted in a significant decrease in N/C interaction. Over
90% of normal alleles fall within the Q16-Q29 range both
in this study and in Buchanan's re-examination of pub-
lished data [69]. Q-tracts in AR equal to or longer than 38
glutamines cause the polyglutamine expansion disorder
spinal and bulbar muscular atrophy while short Q-tracts
are associated with increased risk of prostate cancer [69].
In other genes, Q-tracts with no length variation suggest
the presence of strong purifying selection in which a pre-
cise Q-tract length is required to maintain a protein's
structure or its biomolecular interactions, and its func-
tion. Therefore, a length change in a non-variant Q-tract is
presumed to be lethal.
CAGpolyQ Gene Functions
Based on GO overrepresentation and shared-term analysis
we find that CAGpolyQ genes are involved, in general, in
two major biological processes, DNA dependent regula-
tion of transcription and neurogenesis, and are enriched
for transcriptional coactivator and transcription factor
binding functions. Subgroups of genes such as known
polyglutamine expansion disease genes, priority candi-
dates, or genes containing invariant Q-tracts are not obvi-BMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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ously distinguished by association with a particular
process or molecular function. Polyglutamine-containing
proteins in organisms from yeast to humans have been
previously noted to be involved in transcriptional regula-
tion [44-48]. In fact, most eukaryotic repeat containing
proteins are involved in transcription or translation or
interact directly with DNA, RNA or chromatin, irrespec-
tive of the amino acid repeat type [48]. The majority of
repeat-containing proteins perform roles in processes that
require the assembly of large multiprotein or protein/
nucleic acid complexes [48]. Expanded Q-tracts in HD
and ATN1 gene products interfere with CREBBP-activated
gene transcription via interaction of their Q-rich domains
[91,92] and mutant HD targets specific components of
the core transcriptional machinery, in a Q-tract length-
sensitive manner, to disrupt gene expression in cultured
HD cells [55]. We anticipate that continual incorporation
into the GO of newly published information about the
normal functions of polyglutamine expansion disorder
genes will reveal more specific shared functions among
them.
Conclusion
We have characterized the levels of Q-tract length poly-
morphism in 64 CAGpolyQ repeat tracts in a normal
human population, and found a strong positive correla-
tion between uninterrupted CAG-tract length and Q-tract
length variance. The best predictors of known disease
genes were the occurrence of a long uninterrupted CAG-
tract in the reference genome sequence and high Q-tract
length variance in the normal population. Using these cri-
teria we identified eight priority candidate genes for poly-
glutamine expansion disorders based on the presence of
pure CAG-tracts longer and Q-tract variances higher than
the smallest values in known disease genes. Twelve invar-
iant Q-tracts (in eleven genes) are unlikely to be candi-
dates for polyglutamine expansion disorders. Each
CAGpolyQ repeat, including those in known disease
genes, has a unique distribution of Q-tract lengths,
emphasizing the need to characterize each distribution
without making generalizations between loci. This publi-
cation makes freely available for the first time the length
distributions of virtually all of the CAGpolyQ repeats in
the human genome. Using these normal repeat distribu-
tions against which pathogenic expansions can be identi-
fied, we have begun screening for mutations in
individuals clinically diagnosed with SCA or Huntington
disease-like disorders who do not have identified muta-
tions within known disease genes.
Methods
Selection of candidate genes
Candidate genes were identified on the basis of having a
CAG-type simple repeat within the boundaries of a
known gene with five or more tandem glutamine residues
in the peptide sequence of that gene. To accomplish this,
the Simple Repeats table (simpleRepeat.txt.gz) was down-
loaded from the UCSC genome annotation database [59]
for build 33 (April 2003) of the human genome sequence
assembly [58] and uploaded into a local MySQL database.
The Simple Repeats table contained chromosomal loca-
tion coordinates of all repeats detected by Tandem Repeat
Finder (TRF) software [93] using default parameters. Loca-
tions of all the CAG-type repeats in this table were
exported to a file using an SQL query to extract all records
with the sequences 'CAG', 'AGC', 'CGA', 'CTG', 'GCT' and
'TCG' to accommodate all six potential reading frames of
the repeat as they might appear in genomic sequence. This
file was used as input to a Perl script that used the
Ensembl Perl API [60] version 15_33 to extract all known
genes (Ensembl-predicted transcripts that map to species-
specific SwissProt, RefSeq or TrEMBL database entries)
whose chromosomal coordinates overlapped with the
repeat coordinates. For each known gene with a CAG-type
repeat, if the Ensembl peptide sequence contained five or
more glutamine residues in tandem, that gene was consid-
ered a candidate. A minimum glutamine repeat length of
five was used since Karlin [94] determined that for a "typ-
ical" protein of 400 residues and average composition, a
run of an individual amino acid is statistically significant
if it is five or more residues long [94].
The candidate gene list was generated from Build 33 of the
human genome sequence assembly (April 2003), and the
nucleotide/amino acid sequences of each glutamine tract
reported in Table 1 were generated from Build 35 (May
2004). Two new candidate genes were identified in the
later build (Ensembl known genes data set version
30_35c) that were not part of our study: MKL1  and
C14orf43, and additional CAGpolyQ repeats were
detected in nine of our existing candidate genes: FOXP2,
MAML3, MED12, MINK1, MLL2, MN1, NCOA6, NFAT5,
PAXIP1L. These targets have been denoted by an asterisk
in Table 1. Chromosome band was obtained from the
UCSC Chromosome band track [95] and may differ
slightly from a gene's location listed by the HGNC Data-
base, Genew [14]. Gene names listed are official HGNC
gene symbols from the HGNC website [96] (accessed
March 13, 2007).
DNA samples
Control DNA samples (extracted from blood) were from
a population of mixed ethnic background with individu-
als of Western European descent most highly represented
(Additional file 1). 48 of these were from the Coriell Cell
Repository [97].
PCR primers and amplification of candidate repeats
Additional file 9 lists primer sequences, annealing tem-
peratures, specific PCR conditions and expected fragmentBMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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size (from the reference genome) for each repeat target.
PCR primers for candidate repeat amplification were
designed using Primer3 [98]. Forward primers were 5'-
labeled with 5-HEX, 6-FAM or TAMRA fluorescent dyes
(Operon) and reverse primers all had a 5'-GTTT "PIG-tail"
[99]. PCR amplification was performed with standard Taq
polymerase (Invitrogen) or AccuPrime Taq polymerase
(Invitrogen) in 96-well plates according to the conditions
specified for each target in Additional file 9. PCR products
were visualized and quantitated by comparing the signal
intensity of a specific volume of PCR product against 4 μl
of Low DNA Mass Ladder (Invitrogen) on an agarose gel.
The accuracy of this quantitation method was validated
against the PicoGreen® dsDNA Quantitation assay (Molec-
ular Probes) [100].
ABI 3700 fragment analysis and GeneMapper band calling
PCR products for fragment sizing were assembled in 96-
well microtiter plates at 0.5 ng/μl in each well, with up to
six PCR products multiplexed per well according to their
predicted allele sizes and fluorescent labels. One micro-
liter of the multiplexed PCR products was added to 9 μl of
either 2% 400 HD [ROX] sizing standard (Applied Biosys-
tems) or 2% 500 [ROX] sizing standard (Applied Biosys-
tems) depending on the estimated sizes of products being
analyzed. DNA fragments were separated by capillary elec-
trophoresis using the ABI Prism 3700 DNA Analyzer
(Applied Biosystems) with POP-6 polymer (Applied Bio-
systems). Sizing of the PCR fragments was accomplished
using GeneMapper software (v.3.0, Applied Biosystems).
Representative alleles from each locus were sequenced to
determine the exact correspondence between fragment
size and Q-tract length. In all cases (except TNRC15, for
which we do not present data), fragment length polymor-
phism was entirely accounted for by changes in Q-tract
length. At least one such sequenced allele was included on
every run as a calibrator.
Data management and analysis
Repeat information, PCR conditions, sample information
and analysis results were stored in a MySQL database
called GeMSdb (Genomic Mutational Signature
sequences database). Data was input into GeMSdb using
Perl scripts and through a web interface built with PHP
and Apache. Data analysis and graphics were done using
PHP.
The Q-tract length of each allele was based on the differ-
ence between observed PCR fragment size from a DNA
sample and expected PCR fragment size from the refer-
ence genome (plus 4 nucleotides from the primer tail).
Expected fragment sizes and Q-tract lengths (reference
genome Build 35) for every target are listed in Additional
file 9. Q-tract lengthExp below is that of the longest unin-
terrupted Q-tract in the target. For example, the ATXN1 Q-
tract (Q12H1Q1H1Q14) lengthExpis 14 because the overall
repeat region of 29 residues is interrupted by two non-
glutamine amino acids.
Q-tract lengthObs =
(Fragment sizeObs - Fragment sizeExp)/3 + Q-tract lengthExp
Repeat purity was calculated as a normalized weighted
measure, nWP, combining both the length of the longest
uninterrupted CAG-tract (CAG-length) and the total Q-
tract length (Q-length) of each repeat. Weighted purity
(WP) for each repeat was normalized by dividing by the
highest WP among loci, which was 21.04 for AR.
nWP = (CAG-length/Q-length)*CAG-length/21.04
Statistical analysis
Because there was no a priori knowledge of the distribu-
tion of Q-tract lengths in each gene for the typical control
population, we applied the statistics of tolerance levels to
determine the number of control alleles that must be
screened to distinguish a Q-tract length that occurs in the
affected but not unaffected populations with a given level
of confidence. Screening 130 control alleles provides us
with 99% confidence that 95% of the population of inter-
est lies between the minimum and maximum repeat
lengths in our samples [101].
Gene expression
Candidate genes' expression in brain was determined
according to either eVOC controlled vocabularies for gene
expression data [63,64] queried through BioMart [65] or
according to expression data at the GeneCards website
[66] (accessed September 19, 2005).
Gene functional classification
Gene Ontology over-representation analysis
We used GoMiner [67] for GO over-representation analy-
sis down to the fourth level in the ontology. The target and
background gene sets were generated as follows. We
downloaded 23,913 HGNC gene IDs on June 28, 2005
from the HGNC website [96]. All IDs ending in '~with-
drawn' were removed to generate a list of 21,591 IDs used
as the 'query gene file' for GoMiner. GoMiner matched
13,598 of these to GO terms. We conducted 100 negative
control replicates of this experiment for the three GO cat-
egories, each replicate with 56 randomly selected genes
out of the 13,598 background gene set. To correct for mul-
tiple testing we used a Bonferroni correction to adjust the
threshold of significance appropriately. The raw threshold
of significance was p = 0.05. Adjusted significance thresh-
olds were: molecular function p = 0.00004; biological
process p = 0.00005; cellular component p = 0.00009.BMC Genomics 2007, 8:126 http://www.biomedcentral.com/1471-2164/8/126
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Graph-based shared Gene Ontology term analysis
For each pair of genes among our set of 64, the GO terms
annotated to each gene were compared and we calculated
a graph-based similarity measure (AMM, SLB, BFFO, man-
uscript in preparation) for all gene pairs. In order to deter-
mine significant scores and produce a meaningful
subgraph, we bootstrapped an estimate of the score
required to be above the 99th percentile for a set of genes
of that size (64) from the background set. We randomly
drew 1000 replicates from the set of 15,168 Entrez Gene
human protein-coding genes and took the mean of the
99th percentile score for each GO namespace (biological
process, molecular function and cellular component) as
our cut-off value. Pairs of genes with shared GO terms
scoring above the cut-off value were visualized using
Cytoscape 2.1 [102] with the "organic" arrangement of
nodes, which produced a natural set of clusters. The
"organic" node arrangement treats edges as springs: the
more edges among a group of nodes, the tighter they clus-
ter. The pairwise similarity measure links GO terms via
their lowest common ancestor term in the graph. These
lowest common ancestor terms are output with each pair
of GO terms that are scored, and can be considered as
edge labels in the resulting graph. Clusters of genes joined
by the same GO term edge labels were manually anno-
tated with those GO terms.
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